The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice

PLoS Neglected Tropical Diseases

Volumn 10, Issue 7, 2016, Pages

  Hess, Jessica A ^a   Zhan, Bin ^b,c   Torigian, April R ^a   Patton, John B ^a   Petrovsky, Nikolai ^d,e   Zhan, Tingting ^a   Bottazzi, Maria Elena ^b,c   Hotez, Peter J ^b,c   Klei, Thomas R ^f   Lustigman, Sara ^g   Abraham, David ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d FLINDERS UNIVERSITY   (Australia)

^e VAXINE PTY LTD   (Australia)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ADVAX 2; ALUMINUM POTASSIUM SULFATE; ANTIGEN; CHEMOKINE; ENDOTOXIN; EOTAXIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MIFAMURTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OV 103; OV RAL 2; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; CYTOKINE; HELMINTH ANTIBODY; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; VACCINE;

ANTIGEN ANTIBODY REACTION; ARTICLE; CELL STIMULATION; CRYOPRESERVATION; EOSINOPHIL; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MACROPHAGE; MALE; MORBIDITY; MOUSE; NEUTROPHIL; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; SIMULIUM DAMNOSUM; SPLEEN CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN; IMMUNOLOGY; PARASITOLOGY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CYTOKINES; HUMANS; MALE; MICE; MICE, INBRED BALB C; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; VACCINATION; VACCINES;

EID: 84980390542     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004797     Document Type: Article

References (98)

1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–323. Epub 2015/09/15. doi: 10.1016/S0140-6736(15)00128-226364544; PubMed Central PMCID: PMC4685753.
2. Foltz JL, Makumbi I, Sejvar JJ, Malimbo M, Ndyomugyenyi R, Atai-Omoruto AD, et al. An Epidemiologic Investigation of Potential Risk Factors for Nodding Syndrome in Kitgum District, Uganda. PloS one. 2013;8(6):e66419. Epub 2013/07/05. doi: 10.1371/journal.pone.006641923823012; PubMed Central PMCID: PMC3688914.
3. Wamala JF, Malimbo M, Tepage F, Lukwago L, Okot CL, Cannon RO, et al. Nodding Syndrome May Be Only the Ears of the Hippo. PLoS neglected tropical diseases. 2015;9(8):e0003880. Epub 2015/08/14. doi: 10.1371/journal.pntd.000388026270048; PubMed Central PMCID: PMC4535877.
4. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS neglected tropical diseases. 2009;3(7):e497. Epub 2009/07/22. doi: 10.1371/journal.pntd.000049719621091; PubMed Central PMCID: PMC2710500.
5. Boatin BA, Richards FO, JrControl of onchocerciasis. Advances in parasitology. 2006;61:349–94. Epub 2006/06/01. doi: 10.1016/S0065-308X(05)61009-316735169.
6. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa?Bulletin of the World Health Organization. 2002;80(5):384–91. Epub 2002/06/22. 12077614; PubMed Central PMCID: PMC2567795.
7. Abraham D, Lucius R, Trees AJ, Immunity to Onchocerca spp. in animal hosts. Trends in parasitology. 2002;18(4):164–71. Epub 2002/05/10. 11998704.
8. Duke BO, Moore PJ, The contributions of different age groups to the transmission of Onchocerciasis in a Cameroon forest village. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1968;62(1):22–8. Epub 1968/01/01. 5639533.
9. Njongmeta LM, Nfon CK, Gilbert J, Makepeace BL, Tanya VN, Trees AJ, Cattle protected from onchocerciasis by ivermectin are highly susceptible to infection after drug withdrawal. International journal for parasitology. 2004;34(9):1069–74. Epub 2004/08/18. doi: 10.1016/j.ijpara.2004.04.01115313133.
10. Ardelli BF, Guerriero SB, Prichard RK, Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Molecular and biochemical parasitology. 2005;143(1):58–66. Epub 2005/07/05. doi: 10.1016/j.molbiopara.2005.05.00615993957.
11. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Annals of tropical medicine and parasitology. 2004;98(4):359–70. Epub 2004/07/02. doi: 10.1179/00034980422500344215228717.
12. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Annals of tropical medicine and parasitology. 2004;98(3):231–49. Epub 2004/05/04. doi: 10.1179/00034980422500325315119969.
13. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO, Boussinesq M, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS neglected tropical diseases. 2007;1(1):e72. Epub 2007/11/09. doi: 10.1371/journal.pntd.000007217989786; PubMed Central PMCID: PMC2041821.
14. Bourguinat C, Pion SD, Kamgno J, Gardon J, Gardon-Wendel N, Duke BO, et al. Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naive patients from Cameroon, and its relationship with fertility of the worms. Parasitology. 2006;132(Pt 2):255–62. Epub 2005/10/04. doi: 10.1017/S003118200500889916197589.
15. Eng JK, Prichard RK, A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated- and ivermectin-treated patients. Molecular and biochemical parasitology. 2005;142(2):193–202. Epub 2005/05/12. doi: 10.1016/j.molbiopara.2005.01.02115885823.
16. Huang YJ, Prichard RK, Identification and stage-specific expression of two putative P-glycoprotein coding genes in Onchocerca volvulus. Molecular and biochemical parasitology. 1999;102(2):273–81. Epub 1999/09/25. 10498183.
17. Kohler P, The biochemical basis of anthelmintic action and resistance. International journal for parasitology. 2001;31(4):336–45. Epub 2001/06/13. 11400692.
18. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK, Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369(9578):2021–9. Epub 2007/06/19. doi: 10.1016/S0140-6736(07)60942-817574093.
19. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18–22. Epub 1997/07/05. doi: 10.1016/S0140-6736(96)11094-19217715.
20. Keenan JD, Hotez PJ, Amza A, Stoller NE, Gaynor BD, Porco TC, et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS neglected tropical diseases. 2013;7(12):e2562. Epub 2013/12/18. doi: 10.1371/journal.pntd.000256224340111; PubMed Central PMCID: PMC3855072.
21. Kim YE, Remme JH, Steinmann P, Stolk WA, Roungou JB, Tediosi F, Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS neglected tropical diseases. 2015;9(4):e0003664. Epub 2015/04/11. doi: 10.1371/journal.pntd.000366425860569; PubMed Central PMCID: PMC4393239.
22. Hotez PJ, Bottazzi ME, Zhan B, Makepeace BL, Klei TR, Abraham D, et al. The Onchocerciasis Vaccine for Africa—TOVA—Initiative. PLoS neglected tropical diseases. 2015;9(1):e0003422. Epub 2015/01/31. doi: 10.1371/journal.pntd.000342225634641; PubMed Central PMCID: PMC4310604.
23. Makepeace BL, Babayan SA, Lustigman S, Taylor DW, The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa. Expert review of vaccines. 2015:1–3. Epub 2015/06/21. doi: 10.1586/14760584.2015.105928126091691.
24. Turner HC, Walker M, Lustigman S, Taylor DW, Basanez MG, Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme. PLoS neglected tropical diseases. 2015;9(7):e0003938. Epub 2015/07/18. doi: 10.1371/journal.pntd.000393826186715.
25. Abraham D, Lange AM, Yutanawiboonchai W, Trpis M, Dickerson JW, Swenson B, et al. Survival and development of larval Onchocerca volvulus in diffusion chambers implanted in primate and rodent hosts. The Journal of parasitology. 1993;79(4):571–82. Epub 1993/08/01. 8331478.
26. Abraham D, Leon O, Schnyder-Candrian S, Wang CC, Galioto AM, Kerepesi LA, et al. Immunoglobulin E and eosinophil-dependent protective immunity to larval Onchocerca volvulus in mice immunized with irradiated larvae. Infection and immunity. 2004;72(2):810–7. Epub 2004/01/27. 14742524; PubMed Central PMCID: PMC321619.
27. Johnson EH, Schynder-Candrian S, Rajan TV, Nelson FK, Lustigman S, Abraham D, Immune responses to third stage larvae of Onchocerca volvulus in interferon-gamma and interleukin-4 knockout mice. Parasite immunology. 1998;20(7):319–24. Epub 1998/08/26. 9717193.
28. Lange AM, Yutanawiboonchai W, Lok JB, Trpis M, Abraham D, Induction of protective immunity against larval Onchocerca volvulus in a mouse model. The American journal of tropical medicine and hygiene. 1993;49(6):783–8. Epub 1993/12/01. 8279644.
29. Lange AM, Yutanawiboonchai W, Scott P, Abraham D, IL-4- and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. J Immunol. 1994;153(1):205–11. Epub 1994/07/01. 8207236.
30. Yutanawiboonchai W, Brigandi RA, Rotman HL, Abraham D, Structural and molecular specificity of antibody responses in mice immune to third stage larvae of Onchocerca volvulus. Parasite immunology. 1996;18(2):95–102. Epub 1996/02/01. 9223162.
31. Abraham D, Leon O, Leon S, Lustigman S, Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus. Infection and immunity. 2001;69(1):262–70. Epub 2000/12/19. doi: 10.1128/IAI.69.1.262-270.200111119514; PubMed Central PMCID: PMC97880.
32. Lustigman S, James ER, Tawe W, Abraham D, Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends in parasitology. 2002;18(3):135–41. Epub 2002/02/21. 11854092.
33. Hess JA, Zhan B, Bonne-Annee S, Deckman JM, Bottazzi ME, Hotez PJ, et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. International journal for parasitology. 2014;44(9):637–46. Epub 2014/06/08. doi: 10.1016/j.ijpara.2014.04.00624907553; PubMed Central PMCID: PMC4118642.
34. Arumugam S, Wei J, Liu Z, Abraham D, Bell A, Bottazzi ME, et al. Vaccination of gerbils with Bm-103 and Bm-RAL-2 concurrently or as a fusion protein confers consistent and improved protection against Brugia malayi infections. PLoS neglected tropical diseases. 2016;In Press.
35. Fujiwara RT, Zhan B, Mendez S, Loukas A, Bueno LL, Wang Y, et al. Reduction of worm fecundity and canine host blood loss mediates protection against hookworm infection elicited by vaccination with recombinant Ac-16. Clinical and vaccine immunology: CVI. 2007;14(3):281–7. Epub 2007/02/03. doi: 10.1128/CVI.00404-0617267592; PubMed Central PMCID: PMC1828853.
36. Ramachandran S, Kumar MP, Rami RM, Chinnaiah HB, Nutman T, Kaliraj P, et al. The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination. Microbiology and immunology. 2004;48(12):945–55. Epub 2004/12/22. 15611611.
37. Tsuji N, Miyoshi T, Islam MK, Isobe T, Yoshihara S, Arakawa T, et al. Recombinant Ascaris 16-Kilodalton protein-induced protection against Ascaris suum larval migration after intranasal vaccination in pigs. The Journal of infectious diseases. 2004;190(10):1812–20. Epub 2004/10/23. doi: 10.1086/42507415499538.
38. Tsuji N, Suzuki K, Kasuga-Aoki H, Isobe T, Arakawa T, Matsumoto Y, Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum. Infection and immunity. 2003;71(9):5314–23. Epub 2003/08/23. 12933879; PubMed Central PMCID: PMC187325.
39. Tsuji N, Suzuki K, Kasuga-Aoki H, Matsumoto Y, Arakawa T, Ishiwata K, et al. Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice. Infection and immunity. 2001;69(12):7285–92. Epub 2001/11/14. doi: 10.1128/IAI.69.12.7285-7292.200111705899; PubMed Central PMCID: PMC98813.
40. Wang SH, Zheng HJ, Dissanayake S, Cheng WF, Tao ZH, Lin SZ, et al. Evaluation of recombinant chitinase and SXP1 antigens as antimicrofilarial vaccines. The American journal of tropical medicine and hygiene. 1997;56(4):474–81. Epub 1997/04/01. 9158061.
41. Zhan B, Wang Y, Liu Y, Williamson A, Loukas A, Hawdon JM, et al. Ac-SAA-1, an immunodominant 16 kDa surface-associated antigen of infective larvae and adults of Ancylostoma caninum. International journal for parasitology. 2004;34(9):1037–45. Epub 2004/08/18. doi: 10.1016/j.ijpara.2004.04.01515313130.
42. Bradley JE, Tuan RS, Shepley KJ, Tree TI, Maizels RM, Helm R, et al. Onchocerca volvulus: characterization of an immunodominant hypodermal antigen present in adult and larval parasites. Experimental parasitology. 1993;77(4):414–24. Epub 1993/12/01. doi: 10.1006/expr.1993.11018253155.
43. Lustigman S, Brotman B, Johnson EH, Smith AB, Huima T, Prince AM, Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigen. Molecular and biochemical parasitology. 1992;50(1):79–93. Epub 1992/01/01. 1542318.
44. Beck L, Spiegelberg HL, The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant. Cellular immunology. 1989;123(1):1–8. Epub 1989/10/01. 2776217.
45. Rubin RL, Tang FL, Lucas AH, Spiegelberg HL, Tan EM, IgG subclasses of anti-tetanus toxoid antibodies in adult and newborn normal subjects and in patients with systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity. J Immunol. 1986;137(8):2522–7. Epub 1986/10/15. 3760565.
46. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J, In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. European journal of immunology. 1996;26(9):2062–6. Epub 1996/09/01. doi: 10.1002/eji.18302609158814247.
47. Ghimire TR, The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SpringerPlus. 2015;4:181. Epub 2015/05/02. doi: 10.1186/s40064-015-0972-025932368; PubMed Central PMCID: PMC4406982.
48. Kenney JS, Hughes BW, Masada MP, Allison AC, Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. Journal of immunological methods. 1989;121(2):157–66. Epub 1989/07/26. 2474611.
49. Mori A, Oleszycka E, Sharp FA, Coleman M, Ozasa Y, Singh M, et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. European journal of immunology. 2012;42(10):2709–19. Epub 2012/07/11. doi: 10.1002/eji.20124237222777876.
50. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol. 1999;162(7):3942–9. Epub 1999/04/14. 10201913.
51. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. The Journal of experimental medicine. 2008;205(4):869–82. Epub 2008/03/26. doi: 10.1084/jem.2007108718362170; PubMed Central PMCID: PMC2292225.
52. Lu F, Hogenesch H, Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. Vaccine. 2013;31(37):3979–86. Epub 2013/06/19. doi: 10.1016/j.vaccine.2013.05.10723770306.
53. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A, The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180(8):5402–12. Epub 2008/04/09. 18390722.
54. Cooper PD, Petrovsky N, Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 -> 1] poly(fructo-furanosyl) alpha-D-glucose polymers. Glycobiology. 2011;21(5):595–606. Epub 2010/12/15. doi: 10.1093/glycob/cwq20121147758; PubMed Central PMCID: PMC3106373.
55. Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N, Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine. 2014;32(48):6469–77. Epub 2014/10/01. doi: 10.1016/j.vaccine.2014.09.03425267153; PubMed Central PMCID: PMC4253909.
56. Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine. 2012;30(36):5407–16. Epub 2012/06/22. doi: 10.1016/j.vaccine.2012.06.00922717330; PubMed Central PMCID: PMC3410954.
57. Petrovsky N, Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine. 2006;24Suppl 2:S2–26–9. Epub 2006/07/11. 16823913; PubMed Central PMCID: PMC3101117.
58. Honda-Okubo Y, Saade F, Petrovsky N, Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30(36):5373–81. Epub 2012/06/26. doi: 10.1016/j.vaccine.2012.06.02122728225; PubMed Central PMCID: PMC3401346.
59. Saade F, Honda-Okubo Y, Trec S, Petrovsky N, A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31(15):1999–2007. Epub 2013/01/12. doi: 10.1016/j.vaccine.2012.12.07723306367; PubMed Central PMCID: PMC3606636.
60. Gnjatic S, Sawhney NB, Bhardwaj N, Toll-like receptor agonists: are they good adjuvants?Cancer J. 2010;16(4):382–91. Epub 2010/08/10. doi: 10.1097/PPO.0b013e3181eaca6520693851; PubMed Central PMCID: PMC2922045.
61. Krieg AM, Antiinfective applications of toll-like receptor 9 agonists. Proceedings of the American Thoracic Society. 2007;4(3):289–94. Epub 2007/07/04. doi: 10.1513/pats.200701-021AW17607015; PubMed Central PMCID: PMC2647632.
62. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G, MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959–65. Epub 2009/09/16. doi: 10.1016/j.vaccine.2009.08.10119751689.
63. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R, Safety of MF59 adjuvant. Vaccine. 2008;26(26):3209–22. Epub 2008/05/09. doi: 10.1016/j.vaccine.2008.03.09318462843.
64. Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, et al. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. Archives of virology. 2011;156(3):387–95. Epub 2010/11/27. doi: 10.1007/s00705-010-0860-421110049.
65. Zedda L, Forleo-Neto E, Vertruyen A, Raes M, Marchant A, Jansen W, et al. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. The Pediatric infectious disease journal. 2015;34(1):73–8. Epub 2014/07/19. doi: 10.1097/INF.000000000000046525037034.
66. Steeghs L, Kuipers B, Hamstra HJ, Kersten G, van Alphen L, van der Ley P, Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infection and immunity. 1999;67(10):4988–93. Epub 1999/09/25. 10496868; PubMed Central PMCID: PMC96843.
67. O'Hagan DT, MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert review of vaccines. 2007;6(5):699–710. Epub 2007/10/13. doi: 10.1586/14760584.6.5.69917931151.
68. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26(4):552–61. Epub 2007/12/29. doi: 10.1016/j.vaccine.2007.11.05418162266.
69. Trpis M, Scoles GA, Struble RH, Cryopreservation of infective larvae of Onchocerca volvulus (Filarioidea: Onchocercidae). The Journal of parasitology. 1993;79(5):695–700. Epub 1993/10/01. 8410541.
70. Ekerfelt C, Ernerudh J, Jenmalm MC, Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. Journal of immunological methods. 2002;260(1–2):55–67. Epub 2002/01/17. 11792376.
71. Brattig N, Nietz C, Hounkpatin S, Lucius R, Seeber F, Pichlmeier U, et al. Differences in cytokine responses to Onchocerca volvulus extract and recombinant Ov33 and OvL3-1 proteins in exposed subjects with various parasitologic and clinical states. The Journal of infectious diseases. 1997;176(3):838–42. Epub 1997/09/18. 9291349.
72. Turaga PS, Tierney TJ, Bennett KE, McCarthy MC, Simonek SC, Enyong PA, et al. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens. Infection and immunity. 2000;68(4):1905–11. Epub 2000/03/18. 10722581; PubMed Central PMCID: PMC97365.
73. Boehm U, Klamp T, Groot M, Howard JC, Cellular responses to interferon-gamma. Annual review of immunology. 1997;15:749–95. Epub 1997/01/01. doi: 10.1146/annurev.immunol.15.1.7499143706.
74. Diemert DJ, Pinto AG, Freire J, Jariwala A, Santiago H, Hamilton RG, et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. The Journal of allergy and clinical immunology. 2012;130(1):169–76 e6. Epub 2012/05/29. doi: 10.1016/j.jaci.2012.04.02722633322.
75. Mahalakshmi N, Aparnaa R, Kaliraj P, Evaluation of immune response elicited by inulin as an adjuvant with filarial antigens in mice model. Scandinavian journal of immunology. 2014;80(4):261–70. Epub 2014/07/22. doi: 10.1111/sji.1220825041426.
76. Lechner CJ, Gantin RG, Seeger T, Sarnecka A, Portillo J, Schulz-Key H, et al. Chemokines and cytokines in patients with an occult Onchocerca volvulus infection. Microbes and infection / Institut Pasteur. 2012;14(5):438–46. Epub 2011/12/29. doi: 10.1016/j.micinf.2011.12.00222202179.
77. Bozic CR, Gerard NP, von Uexkull-Guldenband C, Kolakowski LF, Jr.Conklyn MJ, Breslow R, et al. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. The Journal of biological chemistry. 1994;269(47):29355–8. Epub 1994/11/25. 7961909.
78. Cochran BH, Reffel AC, Stiles CD, Molecular cloning of gene sequences regulated by platelet-derived growth factor. Cell. 1983;33(3):939–47. Epub 1983/07/01. 6872001.
79. Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, Thelen M, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. The Journal of experimental medicine. 1997;185(12):2171–6. Epub 1997/06/16. 9182688; PubMed Central PMCID: PMC2196360.
80. Laing KJ, Secombes CJ, Chemokines. Developmental and comparative immunology. 2004;28(5):443–60. Epub 2004/04/06. doi: 10.1016/j.dci.2003.09.00615062643.
81. Johnson EH, Irvine M, Kass PH, Browne J, Abdullai M, Prince AM, et al. Onchocerca volvulus: in vitro cytotoxic effects of human neutrophils and serum on third-stage larvae. Trop Med Parasitol. 1994;45(4):331–5. Epub 1994/12/01. 7716398.
82. Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Gallegos C, et al. Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. The Journal of experimental medicine. 1988;167(6):1939–44. Epub 1988/06/01. 3290382; PubMed Central PMCID: PMC2189692.
83. Sherry B, Tekamp-Olson P, Gallegos C, Bauer D, Davatelis G, Wolpe SD, et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. The Journal of experimental medicine. 1988;168(6):2251–9. Epub 1988/12/01. 3058856; PubMed Central PMCID: PMC2189160.
84. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. The Journal of experimental medicine. 1988;167(2):570–81. Epub 1988/02/01. 3279154; PubMed Central PMCID: PMC2188834.
85. Deshmane SL, Kremlev S, Amini S, Sawaya BE, Monocyte chemoattractant protein-1 (MCP-1): an overview. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2009;29(6):313–26. Epub 2009/05/16. doi: 10.1089/jir.2008.002719441883; PubMed Central PMCID: PMC2755091.
86. Luster AD, Rothenberg ME, Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. Journal of leukocyte biology. 1997;62(5):620–33. Epub 1997/11/19. 9365117.
87. Bonne-Annee S, Kerepesi LA, Hess JA, O'Connell AE, Lok JB, Nolan TJ, et al. Human and mouse macrophages collaborate with neutrophils to kill larval Strongyloides stercoralis. Infection and immunity. 2013;81(9):3346–55. Epub 2013/06/27. doi: 10.1128/IAI.00625-1323798541; PubMed Central PMCID: PMC3754234.
88. Lalani T, Simmons RK, Ahmed AR, Biology of IL-5 in health and disease. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 1999;82(4):317–32; quiz 32–3. Epub 1999/05/05. doi: 10.1016/S1081-1206(10)63281-410227331.
89. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S, Interleukin-17. International reviews of immunology. 1998;16(5–6):541–51. Epub 1998/07/01. 9646176.
90. Laan M, Lotvall J, Chung KF, Linden A, IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. British journal of pharmacology. 2001;133(1):200–6. Epub 2001/04/28. doi: 10.1038/sj.bjp.070406311325811; PubMed Central PMCID: PMC1572774.
91. Spriggs MK, Interleukin-17 and its receptor. Journal of clinical immunology. 1997;17(5):366–9. Epub 1997/11/05. 9327335.
92. Hoshino H, Lotvall J, Skoogh BE, Linden A, Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins. American journal of respiratory and critical care medicine. 1999;159(5 Pt 1):1423–8. Epub 1999/05/06. doi: 10.1164/ajrccm.159.5.980600810228105.
93. Van Kooten C, Boonstra JG, Paape ME, Fossiez F, Banchereau J, Lebecque S, et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. Journal of the American Society of Nephrology: JASN. 1998;9(8):1526–34. Epub 1998/08/11. 9697677.
94. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C, Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. Journal of the American Society of Nephrology: JASN. 2000;11(11):2044–55. Epub 2000/10/29. 11053480.
95. Gewiese-Rabsch J, Drucker C, Malchow S, Scheller J, Rose-John S, Role of IL-6 trans-signaling in CCl(4)induced liver damage. Biochimica et biophysica acta. 2010;1802(11):1054–61. Epub 2010/08/10. doi: 10.1016/j.bbadis.2010.07.02320691261.
96. Jones SA, Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005;175(6):3463–8. Epub 2005/09/09. 16148087.
97. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C, IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends in immunology. 2003;24(1):25–9. Epub 2002/12/24. 12495721.
98. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S, The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et biophysica acta. 2011;1813(5):878–88. Epub 2011/02/08. doi: 10.1016/j.bbamcr.2011.01.03421296109.